摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-1-n-cbz-3-n-boc-氨基吡咯烷 | 122536-74-7

中文名称
(S)-1-n-cbz-3-n-boc-氨基吡咯烷
中文别名
(S)-3-叔丁氧羰基氨基吡咯烷-1-甲酸苄酯
英文名称
(S)-3-<<(1,1-dimethylethoxy)carbonyl>amino>-1-pyrrolidinecarboxylic acid phenylmethyl ester
英文别名
benzyl (3S)-3-(tert-butoxycarbonylamino)pyrrolidine-1-carboxylate;benzyl (S)-3-((tert-butoxycarbonyl)amino)pyrrolidine-1-carboxylate;(S)-benzyl 3-(tert-butoxycarbonylamino)pyrrolidine-1-carboxylate;(3S)-3-tert-butoxycarbonylamino-pyrrolidine-1-carboxylic acid benzyl ester;1-Cbz-3S-(t-butyloxycarbonylamino)pyrrolidine;S-1-Cbz-3-Boc-aminopyrrolidine;benzyl (3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]pyrrolidine-1-carboxylate
(S)-1-n-cbz-3-n-boc-氨基吡咯烷化学式
CAS
122536-74-7
化学式
C17H24N2O4
mdl
——
分子量
320.389
InChiKey
VCCUTXNUDLVCTI-AWEZNQCLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    124-125℃
  • 沸点:
    458.5±44.0 °C(Predicted)
  • 密度:
    1.17

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    23
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    67.9
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933990090

SDS

SDS:8b404ea42f542628e7ef2228a64aaf2a
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (S)-1-n-cbz-3-n-boc-氨基吡咯烷 在 5%-palladium/activated carbon 氢气 、 sodium hydride 作用下, 以 甲醇乙醇N,N-二甲基甲酰胺 、 mineral oil 为溶剂, 反应 24.0h, 生成 (S)-3-N-BOC-N-甲基氨基吡咯烷
    参考文献:
    名称:
    [EN] TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS
    [FR] COMPOSÉS DE TRIAZOLOPYRIDINE EN TANT QU'INHIBITEURS DE KINASE PIM
    摘要:
    式I的化合物:其中R1、R2、R3、R4和R10的含义如规范中所述,在通过PIM-1和/或PIM-2和/或PIM-3激酶介导的疾病治疗中有用的受体酪氨酸激酶抑制剂。
    公开号:
    WO2012154274A1
  • 作为产物:
    描述:
    (R)-3-<(methylsulfonyl)oxy>-1-pyrrolidinecarboxylic acid phenylmethyl ester sodium hydroxide 、 sodium azide 、 氢气 作用下, 以 甲醇N,N-二甲基甲酰胺叔丁醇 为溶剂, 21.5~100.0 ℃ 、344.73 kPa 条件下, 反应 23.5h, 生成 (S)-1-n-cbz-3-n-boc-氨基吡咯烷
    参考文献:
    名称:
    Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity
    摘要:
    A series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)-6-fluoro-1,8-naphthyridine-3-carboxylic acids, 1-cyclopropyl-6,8-difluoro-3-quinolinecarboxylic acids, 1-cyclopropyl-6-fluoro-3-quinolinecarboxylic acids, and 5-amino-1-cyclopropyl-6,8-difluoro-3-quinolinecarboxylic acids have been prepared and evaluated for comparative antibacterial activity. Compounds were prepared by acylation of the 3-amino group of the pyrrolidine with common amino acids using standard peptide chemistry. This series has been compared with the parent compounds for antibacterial activity in vitro and in vivo as well as for comparatively solubility. The amino acid analogues were less active in vitro, but had equal or increased efficacy in vivo. Indeed, it was proven that these compounds, which were stable to acid and base under the reaction conditions for their preparation, were rapidly cleaved in serum to give the parent quinolones. The amino acid derivatives showed a 3-70 times improved solubility when compared to the parent compounds. The most active compound of the series was [S-(R*,R*)]-7-[3-[2-amino-1-oxopropyl)-amino]-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid (PD 131112).
    DOI:
    10.1021/jm00088a011
点击查看最新优质反应信息

文献信息

  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    申请人:Castro C. Alfredo
    公开号:US20060025460A1
    公开(公告)日:2006-02-02
    One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    本发明的一个方面涉及结合到bcl蛋白并抑制Bcl功能的杂环化合物。本发明的另一个方面涉及包含本发明的杂环化合物的组合物。本发明提供了用于治疗和调节与过度增殖相关的疾病,如癌症的方法。
  • FUSED HETEROCYCLIC COMPOUND
    申请人:Lee Chang Seok
    公开号:US20110166121A1
    公开(公告)日:2011-07-07
    The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.
    本发明涉及具有化学式1的融合杂环化合物,其作为血小板聚集抑制剂有用,以及制备该化合物的方法,以及包含该化合物的用于抑制血小板聚集的药物组合物。
  • [EN] TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDINE EN TANT QU'INHIBITEURS DE KINASE PIM
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2012154274A1
    公开(公告)日:2012-11-15
    Compounds of Formula I: in which R1, R2, R3, R4 and R10 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.
    式I的化合物:其中R1、R2、R3、R4和R10的含义如规范中所述,在通过PIM-1和/或PIM-2和/或PIM-3激酶介导的疾病治疗中有用的受体酪氨酸激酶抑制剂。
  • Amidoheterocycles as modulators of the melanocortin-4 receptor
    申请人:——
    公开号:US20040224901A1
    公开(公告)日:2004-11-11
    Novel azetidinyl and pyrrolidinyl compounds are ligands of melanocortin-4 receptors and are useful for treating conditions responsive to the modulation of melanocortin-4 receptors such as obesity, diabetes, and sexual dysfunction. 1
    新型的氮杂环丙烷和吡咯烷化合物是黑色素皮质激素受体的配体,并且可用于治疗对黑色素皮质激素受体调节敏感的疾病,如肥胖、糖尿病和性功能障碍。
  • Antithrombotic agents
    申请人:——
    公开号:US20040010017A1
    公开(公告)日:2004-01-15
    This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.
    本申请涉及到公式I的化合物(或其前药或其药学上可接受的盐或前药),如本文所定义,以及其药物组合物,以及其作为因子Xa抑制剂的用途,以及其制备方法和中间体。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐